PDCD1 and colorectal carcinoma: On the other hand, for WT CRC tumors, complete responses were observed in 0%, 10%, 20% and 50% cases for anti-PD-1/TIM3, anti-PD-1/TIGIT, anti-PD-1/LAG3 and anti-PD1/LAG3/CTLA4 respectively (Figure 4 B, Extended Figure 15 B).